Position in KALV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$679,387
+$489,509 QoQ
Shares Held
33,750
+100.9% QoQ
Ownership
0.063%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#90
of 182 holders
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Common Shares in KALV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Quarry LP holds $18,543,179 across 42 Biotechnology names. KALV ranks #5 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
59,263 | $5,763,326 | |
| 2 | RNA |
Atrium Therapeutics, Inc.
|
66,651 | $891,123 | |
| 3 | PRAX |
Praxis Precision Medicines, Inc.
|
2,750 | $886,022 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
5,000 | $845,100 | |
| 5 | KALV |
KalVista Pharmaceuticals, Inc.
This page
|
33,750 | $679,387 | |
| 6 | FOLD |
AMICUS THERAPEUTICS, INC.
|
46,220 | $668,341 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
10,000 | $564,900 | |
| 8 | VSTM |
Verastem, Inc.
|
100,000 | $530,000 |
All Filings in KALV
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $679,387 | 33,750 | Shares | Other | 2026-05-15 | |
| 2025-06-30 | $189,878 | 16,796 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $96,936 | 8,400 | Shares | Other | 2025-05-15 | |
| 2024-03-31 | $11,860 | 1,000 | Shares | Other | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||